Otsuka’s lupus nephritis drug Lupkynis backed for NHS use

Patients in England and Wales with active lupus nephritis will soon be able to access treatment with Otsuka Pharma’s Lupkynis following a recommendation by the health tech

Otsuka, Aurinia claim EU okay for oral lupus nephritis drug

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupu

FDA approves AZ's anifrolumab, ending 10-year lupus drug dro...

AstraZeneca has completed the resurrection of its anifrolumab drug for systemic lupus erythematosus (SLE) after claiming FDA approval for the drug as an add-on therapy for adults with the a

GSK’s Benlysta claims first FDA okay for lupus kidney damage

GlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up its sleeve – it’s just become the first and only FDA-approved treatment for lupus neph

AZ fleshes out positive trial of revitalised lupus drug anif...

Aurinia scores big win in lupus nephritis trial

Small biopharma company Aurinia has released promising results of its candidate for lupus nephritis (LN) claiming it to be the first ever to show efficacy against the condition.